Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance
Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance
SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday, January 8, 2025, at 5:30 a.m. PT / 8:30 a.m. ET.
聖地亞哥，2025年1月6日 /PRNewswire/ -- 奧洛茲美醫療公司（納斯達克：HALO）（"奧洛茲美"）今天宣佈將於2025年1月8日星期三上午5:30（太平洋時間）/ 上午8:30（東部時間）舉行投資者電話會議。
On the call, Dr. Helen Torley, President and Chief Executive Officer, and Nicole LaBrosse, Chief Financial Officer, will provide preliminary unaudited full year 2024 results and updated 2025 and multi-year financial guidance.
在電話會議上，首席執行官兼總裁Helen Torley博士和財務長Nicole LaBrosse將提供2024財年初步未經審計的全年度業績以及更新的2025年和多年度財務指引。
Pre-registration of the live call can be accessed via link here: . The call will also be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast and presentation materials, which will be available 15 minutes before the call, please visit Halozyme.com.
可以通過鏈接訪問現場電話會議的預註冊。該電話會議還將在奧洛茲美的公司網站「投資者」部分進行現場直播網絡廣播，並將在會議結束後提供錄音。要訪問網絡廣播和演示材料（將在會議前15分鐘提供），請訪問Halozyme.com。
About Halozyme
關於奧洛茲美
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched more than 800,000 patient lives in post-marketing use in nine commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
奧洛茲美是一家生物製藥公司，致力於推進顛覆性解決方案，以改善患者體驗和治療效果，適用於新興和成熟療法。作爲ENHANZE藥物輸送技術的創新者，憑藉專有酶rHuPH20，奧洛茲美的商業驗證解決方案用於 facilitar 皮下注射藥物和液體的輸送，目標是以快速皮下輸送和減少治療負擔來改善患者體驗。奧洛茲美在九種商業產品的後市場中接觸了超過800,000名患者的生命，覆蓋100多個全球市場，已將其ENHANZE技術授權給領先的藥品和生物技術公司，包括羅氏、武田、輝瑞、揚森、艾伯維公司、禮來、施貴寶、argenx、ViiV Healthcare、中外製藥和Acumen Pharmaceuticals。
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.
奧洛茲美還開發、生產和商業化藥物-設備組合產品，或與合作伙伴一起，使用其先進的自動注射器技術，旨在提供商業或功能優勢，如改善便利性、可靠性和耐受性，以及增強患者的舒適度和遵從性。公司有兩款商業專有產品，Hylenex和XYOSTED，以及與Teva Pharmaceuticals和Idorsia Pharmaceuticals的合作商業產品和持續的產品開發項目。
Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.
奧洛茲美醫療總部位於加州聖地亞哥，並在新澤西州尤因和明尼蘇達州明尼通卡設有辦公室。明尼通卡也是其運營設施的地點。
For more information visit and connect with us on LinkedIn and Twitter.
有關更多信息，請訪問並在LinkedIn和Twitter上與我們聯繫。
Contacts:
聯繫方式：
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
[email protected]
特拉姆·布伊
副總裁，投資者關係和企業溝通
609-359-3016
[email protected]
Samantha Gaspar
Teneo
212-886-9356
[email protected]
薩曼莎·加斯帕
Teneo
212-886-9356
[email protected]
SOURCE Halozyme Therapeutics, Inc.
來源：奧洛茲美醫療公司
